Exousia Bio (LMMY) Reports Going Concern, Pivots to Biotech, Secures Highly Dilutive $250K Convertible Note, and Rescinds 21M Shares

summarizeSummary

Exousia Bio, Inc.'s 10-Q reveals a company in significant financial distress undergoing a complete business transformation. The explicit 'going concern' warning highlights the immediate risk to the company's viability. The pivot from a video game platform to a clinical-stage biotechnology company is a high-risk, high-reward strategy, currently without revenue. The $250,000 convertible note carries extremely predatory 'death spiral' conversion terms, indicating a desperate need for capital and posing a severe threat of massive dilution to existing common shareholders. The issuance of super-voting preferred stock to the majority owner further concentrates control and diminishes the influence of common shareholders. While the rescission of 21 million shares reduces prior dilution, it also points to significant operational or transactional issues in the recent past. Investors should be aware of the extreme financial risk, the speculative nature of the new business, and the highly dilutive and control-concentrating financing structure.

check_boxKey Events

• Going Concern Warning

  The company's financial statements include a 'going concern' warning, indicating substantial doubt about its ability to continue operations due to insufficient revenue to cover costs and an accumulated deficit of $288,623 as of November 30, 2025.

• Business Transformation to Biotechnology

  Effective November 17, 2025, the company acquired Exousia AI, Inc., pivoting its business from an educational video game platform to a clinical-stage biotechnology company focused on oncology. This change also involved a new management team, with Matthew Dwyer appointed as Sole Director and Officer.

• Highly Dilutive Convertible Note Issued

  On January 20, 2026, the company issued a $250,000 convertible promissory note to GBII Partners Inc. with a 15% interest rate (18% on default) and a maturity date of March 26, 2026. The conversion price is initially 50% of the market price, but drops to 35%, 20%, and then 10% of the market price if not paid by maturity, representing highly dilutive 'death spiral' terms. The note is secured by 6,276,225 common shares pledged by majority shareholders.

• 21 Million Shares Rescinded

  Effective March 14, 2026, the company rescinded the issuance of 21,000,000 common shares to Progenicyte Japan CO., LTD., which were part of the November 2025 Exousia AI acquisition, citing a 'mistake of fact.' This reduces the effective outstanding shares from 73,500,000 to 52,500,000.

auto_awesomeAnalysis

Exousia Bio, Inc.'s 10-Q reveals a company in significant financial distress undergoing a complete business transformation. The explicit 'going concern' warning highlights the immediate risk to the company's viability. The pivot from a video game platform to a clinical-stage biotechnology company is a high-risk, high-reward strategy, currently without revenue. The $250,000 convertible note carries extremely predatory 'death spiral' conversion terms, indicating a desperate need for capital and posing a severe threat of massive dilution to existing common shareholders. The issuance of super-voting preferred stock to the majority owner further concentrates control and diminishes the influence of common shareholders. While the rescission of 21 million shares reduces prior dilution, it also points to significant operational or transactional issues in the recent past. Investors should be aware of the extreme financial risk, the speculative nature of the new business, and the highly dilutive and control-concentrating financing structure.